AB Corporate Bond ETF (NASDAQ:EYEG) Stock Passes Below 200-Day Moving Average – Should You Sell?

Posted by Stephan Jacobs on Jul 30th, 2026

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $35.38 and traded as low as $34.58. AB Corporate Bond ETF shares last traded at $34.58, with a volume of 415 shares changing hands.

AB Corporate Bond ETF Trading Down 0.4%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07. The stock has a market capitalization of $27.66 million, a price-to-earnings ratio of -20.58 and a beta of 0.17. The business has a fifty day simple moving average of $35.10 and a 200 day simple moving average of $35.38.

AB Corporate Bond ETF Cuts Dividend

The firm also recently announced a monthly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Wednesday, July 1st were given a $0.1358 dividend. This represents a c) dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date of this dividend was Wednesday, July 1st. AB Corporate Bond ETF’s payout ratio is presently -102.98%.

Hedge Funds Weigh In On AB Corporate Bond ETF

A hedge fund recently raised its stake in AB Corporate Bond ETF stock. Jane Street Group LLC raised its holdings in AB Corporate Bond ETF (NASDAQ:EYEG – Free Report) by 166.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,741 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,839 shares during the period. Jane Street Group LLC owned approximately 2.10% of AB Corporate Bond ETF worth $563,000 at the end of the most recent quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

AB Corporate Bond ETF Company Profile

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.